STOCKHOLM, den 21 december 2023 – Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) meddelar idag att 63 aktier, motsvarande ca 0,5 MSEK, har avyttrats i intressebolaget Emollivet samt att ett lån om ca 0,6 MSEK tagits upp från bolagets största ägare Cerbios-Pharma SA. Under 2023 har Lipidor gjort en stegvis avyttring av innehav […]
STOCKHOLM, Sweden, 20th December 2023 – Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) announces today that the company, through its partner Cliantha Research, has submitted an application to the Indian Medical Products Agency to start a Phase III study with the drug candidate AKP02G2. The main purpose of the study is to compare […]
STOCKHOLM, den 20 december 2023 – Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) meddelar idag att bolaget genom sin samarbetspartner Cliantha Research har lämnat in en ansökan till indiska läkemedelsmyndigheten om att få starta en Fas III-studie med läkemedelskandidaten AKP02G2. Studiens främsta syfte är att jämföra den terapeutiska effekten hos AKP02G2 med Enstilar […]
STOCKHOLM, Sweden, 5th December 2023 – Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) today presents its Nomination Committee, which shall have four members, in accordance with the applicable instructions resolved by the Annual General Meeting 2020. The three largest shareholders who are registered with Euroclear Sweden AB on the last of September before […]
STOCKHOLM, den 5 december 2023 – Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) presenterar idag enligt den gällande instruktionen (beslutad av årsstämman 2020) sin valberedning som ska som bestå av fyra ledamöter. De tre största aktieägarna som är registrerade hos Euroclear Sweden AB den sista september innan stämman ska kontaktas av bolagets styrelseordförande. […]
STOCKHOLM, den 30 november 2023 – Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) meddelar idag att man byter Certified Adviser från Erik Penser Bank AB till Carnegie Investment Bank AB (publ). Lipidor har ingått avtal med Carnegie Investment Bank AB (publ) avseende tjänsten som Certified Adviser. Carnegie Investment Bank AB (publ) tillträder som […]
STOCKHOLM, Sweden, 30th November 2023 – Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) today announces a change of Certified Adviser from Erik Penser Bank AB to Carnegie Investment Bank AB (publ). Lipidor has entered into an agreement with Carnegie Investment Bank AB (publ) regarding the position as Certified Adviser. Carnegie Investment Bank AB […]
STOCKHOLM, Sweden, 22nd November 2023 – Today, Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) publishes its interim report for the period January – September 2023. The report is available on the company's website lipidor.se and in the attached pdf. To read the quarterly report (in Swedish) click here: https://lipidor.se/investors/financial-reports/ Summary of interim report […]
STOCKHOLM, den 22 november 2023 – Idag publicerar Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) sin delårsrapport för perioden januari – september 2023. Kvartalsrapporten finns att hämta på bolagets hemsida lipidor.se samt i form av bifogad pdf. För att läsa kvartalsrapporten för Q3 2023 klicka här: https://lipidor.se/investerare/finansiella-rapporter/ Sammanfattning av delårsrapporten Lipidor arbetar i […]
STOCKHOLM, Sweden, 27th October 2023 – Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) today announces that the company has filed a new patent application with the European Patent Office (EPO). The patent originates from the development that took place during the reformulation work with AKP02, now AKP02G2. In line with Lipidor's strategy, the […]